Skip to main content
Top
Published in: International Journal of Clinical Oncology 2/2019

01-02-2019 | Colorectal Cancer | Original Article

Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients

Authors: Xian Hua Gao, Guan Yu Yu, Yong Gang Hong, Wei Lian, Hanumant Chouhan, Yi Xu, Lian Jie Liu, Chen Guang Bai, Wei Zhang

Published in: International Journal of Clinical Oncology | Issue 2/2019

Login to get access

Abstract

Background

Simultaneous detection of multiple molecular biomarkers is helpful in the prediction of treatment response and prognosis for colorectal cancer (CRC) patients.

Methods

A 22-gene panel consisting of 103 hotspot regions was utilized in the formalin-fixed paraffin-embedded (FFPE) tissue samples of 207 CRC patients, using the next-generation sequencing (NGS)-based multiplex PCR technique. Those 22 genes included AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11, and TP53.

Results

Of the 207 patients, 193 had one or more variants, with 170, 20, and 3 having one, two, and three mutated genes, respectively. Of the total 414 variants identified in this study, 384, 25, and 5 were single-nucleotide variants, deletion, and insertion. The top four frequently mutated genes were TP53, KRAS, PIK3CA, and FBXW7. There was high consistency between the results of NGS–PCR technique and routine ARMS-PCR in KRAS and BRAF mutation detection. Univariate and multivariate analyses demonstrated that advanced TNM stage, elevated serum CEA, total variants number ≥ 2, AKT1 and PTEN mutation were independent predictors of shorter DFS; poor differentiation, advanced TNM stage, total variants number ≥ 2, BRAF, CTNNB1 and NRAS mutation were independent predictors of shorter OS.

Conclusions

It is feasible to detect multiple gene mutations with a 22-gene panel in FFPE CRC specimens. TNM stage and total variants number ≥ 2 were independent predictors of DFS and OS. Detection of multiple gene mutations may provide additional prognostic information to TNM stage in CRC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stewart B, Wild CP (eds) (2014) World Cancer Report 2014. International Agency for Research on Cancer (IARC), Lyon Stewart B, Wild CP (eds) (2014) World Cancer Report 2014. International Agency for Research on Cancer (IARC), Lyon
2.
go back to reference Marmol I, Sanchez-de-Diego C, Pradilla Dieste A et al (2017) Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 18(1):197CrossRefPubMedCentral Marmol I, Sanchez-de-Diego C, Pradilla Dieste A et al (2017) Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 18(1):197CrossRefPubMedCentral
3.
go back to reference Dienstmann R, Mason MJ, Sinicrope FA et al (2017) Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol 28(5):1023–1031CrossRefPubMedPubMedCentral Dienstmann R, Mason MJ, Sinicrope FA et al (2017) Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol 28(5):1023–1031CrossRefPubMedPubMedCentral
4.
go back to reference Normanno N, Rachiglio AM, Roma C et al (2013) Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem 114(3):514–524CrossRefPubMed Normanno N, Rachiglio AM, Roma C et al (2013) Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem 114(3):514–524CrossRefPubMed
5.
go back to reference Garde Noguera J, Jantus-Lewintre E, Gil-Raga M et al (2017) Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: a retrospective analysis. Mol Clin Oncol 6(3):403–408CrossRefPubMedPubMedCentral Garde Noguera J, Jantus-Lewintre E, Gil-Raga M et al (2017) Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: a retrospective analysis. Mol Clin Oncol 6(3):403–408CrossRefPubMedPubMedCentral
6.
go back to reference Tops BB, Normanno N, Kurth H et al (2015) Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer 15:26CrossRefPubMedPubMedCentral Tops BB, Normanno N, Kurth H et al (2015) Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer 15:26CrossRefPubMedPubMedCentral
7.
go back to reference Rey JM, Ducros V, Pujol P et al (2017) Improving mutation screening in patients with colorectal cancer predisposition using next-generation sequencing. J Mol Diagn 19:589–601CrossRefPubMed Rey JM, Ducros V, Pujol P et al (2017) Improving mutation screening in patients with colorectal cancer predisposition using next-generation sequencing. J Mol Diagn 19:589–601CrossRefPubMed
8.
go back to reference Dijkstra JR, Tops BB, Nagtegaal ID et al (2015) The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment. Virchows Arch 467(3):273–278CrossRefPubMedPubMedCentral Dijkstra JR, Tops BB, Nagtegaal ID et al (2015) The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment. Virchows Arch 467(3):273–278CrossRefPubMedPubMedCentral
9.
go back to reference Hadd AG, Houghton J, Choudhary A et al (2013) Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 15(2):234–247CrossRefPubMed Hadd AG, Houghton J, Choudhary A et al (2013) Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 15(2):234–247CrossRefPubMed
10.
go back to reference Zhang J, Zheng J, Yang Y et al (2015) Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Sci Rep 5:18678CrossRefPubMedPubMedCentral Zhang J, Zheng J, Yang Y et al (2015) Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Sci Rep 5:18678CrossRefPubMedPubMedCentral
11.
12.
go back to reference Carpten JD, Faber AL, Horn C et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152):439–444CrossRefPubMed Carpten JD, Faber AL, Horn C et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152):439–444CrossRefPubMed
13.
go back to reference Tian S, Simon I, Moreno V et al (2013) A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 62(4):540–549CrossRefPubMed Tian S, Simon I, Moreno V et al (2013) A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 62(4):540–549CrossRefPubMed
14.
go back to reference Hammerman PS, Sos ML, Ramos AH et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1(1):78–89CrossRefPubMedPubMedCentral Hammerman PS, Sos ML, Ramos AH et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1(1):78–89CrossRefPubMedPubMedCentral
15.
go back to reference Arcila ME, Chaft JE, Nafa K et al (2012) Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 18(18):4910–4918CrossRefPubMed Arcila ME, Chaft JE, Nafa K et al (2012) Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 18(18):4910–4918CrossRefPubMed
16.
go back to reference Al-Shamsi HO, Jones J, Fahmawi Y et al (2016) Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol 7(6):882–902CrossRefPubMedPubMedCentral Al-Shamsi HO, Jones J, Fahmawi Y et al (2016) Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol 7(6):882–902CrossRefPubMedPubMedCentral
17.
go back to reference Jauhri M, Bhatnagar A, Gupta S et al (2017) Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: next-generation sequencing-based cohort study. Tumour Biol 39(2):1010428317692265CrossRefPubMed Jauhri M, Bhatnagar A, Gupta S et al (2017) Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: next-generation sequencing-based cohort study. Tumour Biol 39(2):1010428317692265CrossRefPubMed
18.
go back to reference Chang YS, Chang SJ, Yeh KT et al (2013) RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients. Onkologie 36(12):719–724PubMed Chang YS, Chang SJ, Yeh KT et al (2013) RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients. Onkologie 36(12):719–724PubMed
19.
go back to reference Arrington AK, Heinrich EL, Lee W et al (2012) Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 13(10):12153–12168CrossRefPubMedPubMedCentral Arrington AK, Heinrich EL, Lee W et al (2012) Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 13(10):12153–12168CrossRefPubMedPubMedCentral
21.
go back to reference Loes IM, Immervoll H, Sorbye H et al (2016) Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer 139(3):647–656CrossRefPubMedPubMedCentral Loes IM, Immervoll H, Sorbye H et al (2016) Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer 139(3):647–656CrossRefPubMedPubMedCentral
22.
go back to reference Tran NH, Cavalcante LL, Lubner SJ et al (2015) Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol 7(5):252–262CrossRefPubMedPubMedCentral Tran NH, Cavalcante LL, Lubner SJ et al (2015) Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol 7(5):252–262CrossRefPubMedPubMedCentral
23.
go back to reference Won DD, Lee JI, Lee IK et al (2017) The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. BMC Cancer 17(1):403CrossRefPubMedPubMedCentral Won DD, Lee JI, Lee IK et al (2017) The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. BMC Cancer 17(1):403CrossRefPubMedPubMedCentral
24.
go back to reference Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60 – 00 trial. J Clin Oncol 28(3):466–474CrossRefPubMed Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60 – 00 trial. J Clin Oncol 28(3):466–474CrossRefPubMed
25.
go back to reference Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29(10):1261–1270CrossRefPubMed Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29(10):1261–1270CrossRefPubMed
26.
go back to reference Sinicrope FA, Shi Q, Allegra CJ et al (2017) Association of DNA mismatch repair and mutations in BRAF and kras with survival after recurrence in stage III colon cancers: a secondary analysis of 2 randomized clinical trials. JAMA Oncol 3(4):472–480CrossRefPubMedPubMedCentral Sinicrope FA, Shi Q, Allegra CJ et al (2017) Association of DNA mismatch repair and mutations in BRAF and kras with survival after recurrence in stage III colon cancers: a secondary analysis of 2 randomized clinical trials. JAMA Oncol 3(4):472–480CrossRefPubMedPubMedCentral
27.
go back to reference Nakayama I, Shinozaki E, Matsushima T et al (2017) Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. BMC Cancer 17(1):38CrossRefPubMedPubMedCentral Nakayama I, Shinozaki E, Matsushima T et al (2017) Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. BMC Cancer 17(1):38CrossRefPubMedPubMedCentral
28.
go back to reference Bleeker FE, Felicioni L, Buttitta F et al (2008) AKT1(E17K) in human solid tumours. Oncogene 27(42):5648–5650CrossRefPubMed Bleeker FE, Felicioni L, Buttitta F et al (2008) AKT1(E17K) in human solid tumours. Oncogene 27(42):5648–5650CrossRefPubMed
29.
go back to reference Haggblad Sahlberg S, Mortensen AC, Haglof J et al (2017) Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells. Int J Oncol 50(1):5–14CrossRefPubMed Haggblad Sahlberg S, Mortensen AC, Haglof J et al (2017) Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells. Int J Oncol 50(1):5–14CrossRefPubMed
30.
go back to reference Foltran L, De Maglio G, Pella N et al (2015) Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncol 11(4):629–640CrossRefPubMed Foltran L, De Maglio G, Pella N et al (2015) Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncol 11(4):629–640CrossRefPubMed
31.
go back to reference Wang X, Yang Z, Tian H et al (2017) Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer. Oncotarget 8(15):24892–24901PubMedPubMedCentral Wang X, Yang Z, Tian H et al (2017) Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer. Oncotarget 8(15):24892–24901PubMedPubMedCentral
32.
go back to reference Ohlsson L, Israelsson A, Oberg A et al (2012) Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer. Int J Cancer 130(8):1833–1843CrossRefPubMed Ohlsson L, Israelsson A, Oberg A et al (2012) Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer. Int J Cancer 130(8):1833–1843CrossRefPubMed
33.
go back to reference Rey JM, Ducros V, Pujol P et al (2017) Improving mutation screening in patients with colorectal cancer predisposition using next-generation sequencing. J Mol Diagn 19(4):589–601CrossRefPubMed Rey JM, Ducros V, Pujol P et al (2017) Improving mutation screening in patients with colorectal cancer predisposition using next-generation sequencing. J Mol Diagn 19(4):589–601CrossRefPubMed
34.
go back to reference Lee JW, Soung YH, Kim SY et al (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24(8):1477–1480CrossRefPubMed Lee JW, Soung YH, Kim SY et al (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24(8):1477–1480CrossRefPubMed
35.
go back to reference Cizkova M, Susini A, Vacher S et al (2012) PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 14(1):R28CrossRefPubMedPubMedCentral Cizkova M, Susini A, Vacher S et al (2012) PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 14(1):R28CrossRefPubMedPubMedCentral
37.
go back to reference Mendelsohn J (2013) Personalizing oncology: perspectives and prospects. J Clin Oncol 31(15):1904–1911CrossRefPubMed Mendelsohn J (2013) Personalizing oncology: perspectives and prospects. J Clin Oncol 31(15):1904–1911CrossRefPubMed
Metadata
Title
Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients
Authors
Xian Hua Gao
Guan Yu Yu
Yong Gang Hong
Wei Lian
Hanumant Chouhan
Yi Xu
Lian Jie Liu
Chen Guang Bai
Wei Zhang
Publication date
01-02-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 2/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1377-1

Other articles of this Issue 2/2019

International Journal of Clinical Oncology 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine